Tagged with MP

Hong Kong Dr Joseph Tam is indisputably one of the pioneers of Hong Kong’s biotech industry, having returned to Hong Kong in 1973 following an illustrious career in the US to bring in novel technologies to the city.   I feel happy that I have achieved my initial objectives: to bring international…

Sweden In a market where revolutionary treatments and new technologies threaten to introduce structural changes, the need for national authorities and regulators to adapt and catch up with the pace of the industry is of uttermost importance. Dr Catarina Andersson Forsman, director general of the Swedish Medical Products Agency (MPA), shares…

China 2009 marks 40 years of China’s liberalization and opening up under then-Premier Deng Xiaoping. Servier China also bears the distinction of having been established that year, celebrating its 40th anniversary in tandem with its host country.   The success of Servier China is based on the quality of the people…

Korea ISU Abxis is a biotech company founded in 2001 with a focus on orphan drugs and rare disease. Part of the ISU chaebol, ISU Abxis has leveraged its parent company’s long-standing expertise in chemicals.   We have penetrated the Korean market already, and have received approval in 12 overseas emerging…

Opinion Eurasia Group’s Aditya Bhattacharji and Sarah Hassan identify and unpack the top three political and policy issues that multinational pharmaceutical firms are currently focusing on.   Issue One: The Global Economy Over the past month, one theme stood out at both the central bankers’ confab in Jackson Hole, Wyoming and…

Company Profile As one of the longest-standing multinational companies in Egypt, French pharmaceutical giant Sanofi aims to plays a major role in ensuring access to innovative pharmaceuticals for the Egyptian population through manufacturing locally.   During President Macron’s visit, Sanofi signed a Memorandum of Understanding (MoU) with the Egyptian Ministry of Health…

Spain Though still one of the younger and lesser-known outfits inhabiting the European drug development landscape, Irish-headquartered rare disease specialist, Jazz pharma has been making tremendous headway in the onco-haematology and sleep disorder spaces and the Spanish affiliate is absolutely no exception.   We blend the lessons of art with our…

Spain The global acquisition of GSK’s thrombosis portfolio and subsequent purchase of AstraZeneca’s anaesthesia business have been critical milestones for the maverick South African pharmaceutical outfit Aspen, enabling the company to establish a consolidated presence across Europe, including the opening of the firm’s first-ever Spanish affiliate only two and a half…

Sweden Orifarm is the largest supplier of parallel imported medicines in the EU and a fast-growing supplier of generic pharmaceuticals in the Nordic countries. Christian Vallentin, country manager of Orifarm Sweden, explains the intricacies of the parallel import business and generics market in Sweden, how to successfully compete in both areas,…

China Dr Jun Bao, appointed president and CEO of Impact Therapeutics in October 2018, shares his aspirations for Impact to be a leader in synthetic lethality in oncology; the importance of ‘operating locally but selling globally’; his learnings from his distinguished career across biotech and pharma companies in the US and…

Spain María Jesús Lamas, director and César Hernández García, head of medicines for human use at the Spanish Agency of Medicine and Health Products (AEMPS), discuss the challenges impacting the evaluation and analysis of products today. Furthermore, they give insights into why Spain is a leading global clinical trials destination and…

France Stéphane Mathieu CEO for SIGVARIS GROUP’s Europe, South & West operations, discusses taking on a unique challenge as the company pivots towards becoming a fully-fledged health technology provider, and what ‘patient-centricity’ means to him.   The onus is firmly upon medtech players to become much more “patient-centric” in both their…